Chimeric non-human animal carrying human hepatocyte

US9420769B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-9420769-B2
Application numberUS-201214351481-A
CountryUS
Kind codeB2
Filing dateOct 12, 2012
Priority dateOct 13, 2011
Publication dateAug 23, 2016
Grant dateAug 23, 2016

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

A chimeric non-human animal having an in vivo human hepatocyte population, wherein the effects of non-human animal cells on drug metabolism are suppressed or deleted is provided. A method for producing a chimeric non-human animal that lacks a drug-metabolizing system or has a suppressed drug-metabolizing system and is provided with a drug-metabolizing system driven by human hepatocytes, is provided. The method comprises transplanting human hepatocytes into a non-human animal characterized by (i) being immunodeficient, (ii) having liver damage, and (iii) lacking the functions of an endogenous Cyp3a gene.

First claim

Opening claim text (preview).

The invention claimed is: 1. A method for producing a chimeric mouse, comprising transplanting a human hepatocyte into a mouse, the mouse (i) being immunodeficient, (ii) having liver damage, and (iii) lacking functions of an endogenous Cyp3a gene, wherein the chimeric mouse lacks a drug-metabolizing system from the mouse and is provided with a drug-metabolizing system driven by human hepatocytes. 2. The method according to claim 1 , wherein the mouse into which a human hepatocyte is to be transplanted is obtained by a method comprising performing three-way crossing of a mouse or offspring thereof having genetic immunodeficiency, a mouse or offspring thereof genetically having liver damage, and a mouse or offspring thereof genetically lacking the functions of the endogenous Cyp3a gene. 3. The method according to claim 1 , wherein the mouse into which a human hepatocyte is to be transplanted is obtained by a method comprising crossing a mouse or offspring thereof having genetic immunodeficiency and genetically having liver damage with a mouse or offspring thereof genetically lacking the functions of the endogenous Cyp3a gene. 4. The method according to claim 1 , wherein the mouse into which a human hepatocyte is to be transplanted is obtained by a method comprising crossing a uPA(+/+)/SCID(+/+) mouse with a cyp3a (KO/KO) mouse, and screening for an animal that homozygously has each genetic component. 5. The method according to claim 1 , wherein the mouse into which a human hepatocyte is to be transplanted is a cyp3a(KO/KO)/uPA(+/+)/SCID(+/+) mouse. 6. A chimeric mouse, obtained by the method according to claim 1 . 7. A chimeric mouse, comprising in vivo human hepatocytes, wherein the chimeric mouse lacks functions of the endogenous Cyp3a gene, and carries the in vivo human hepatocytes. 8. The chimeric mouse according to claim 7 , wherein the non-human animal lacks a drug-metabolizing system and is provided with a drug-metabolizing system driven by human hepatocytes. 9. A method of conducting a toxicity study on a test substance, comprising: administering a test substance to the chimeric mouse according to claim 6 ; and evaluating the effects of the test substance on the human hepatocytes. 10. A method for testing a capacity of human hepatocytes to metabolize a test substance, comprising: administering a test substance to the chimeric mouse according to claim 6 ; and evaluating the capacity of human hepatocytes to metabolize the test substance. 11. A method of conducting a toxicity study on a test substance, comprising: administering a test substance to the chimeric mouse according to claim 7 ; and evaluating the effects of the test substance on the human hepatocytes. 12. A method for testing a capacity of human hepatocytes to metabolize a test substance, comprising: administering a test substance to the chimeric mouse according to claim 7 ; and evaluating the capacity of human hepatocytes to metabolize the test substance.

Assignees

Inventors

Classifications

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US9420769B2 cover?
A chimeric non-human animal having an in vivo human hepatocyte population, wherein the effects of non-human animal cells on drug metabolism are suppressed or deleted is provided. A method for producing a chimeric non-human animal that lacks a drug-metabolizing system or has a suppressed drug-metabolizing system and is provided with a drug-metabolizing system driven by human hepatocytes, is prov…
Who is the assignee on this patent?
Oshimura Mitsuo, Kazuki Yasuhiro, Mukaidani Chise, and 10 more
What technology area does this patent fall under?
Primary CPC classification A01K67/0271. Mapped technology areas include Human Necessities.
When was this patent published?
Publication date Tue Aug 23 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).